Video
Latest in Video
Patients with complete response can have long treatment-free interval, study suggests
And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission
Our panel of experts discuss when might be the right time to reduce therapy
Our panel of experts discuss when might be the right time to reduce therapy
More in Video
Faranak Kamangar on how the AI tool can be used in practice to make life easier for physicians
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
Our understanding of eczema's potential comorbidities will likely expand, says Lakshi Aldredge
We've got great treatments, says Steven Feldman, the key is getting patients to use them
James Del Rosso, DO, says to keep an open mind when determining the best option for patients
Will be good news for patients when drug is approved, says Emma Guttman-Yassky, MD, PhD